09:25 AM EDT, 08/04/2025 (MT Newswires) -- Sonnet BioTherapeutics ( SONN ) said Monday it plans to expand its ongoing phase 1b/2a trial of SON-1010 plus atezolizumab in patients with platinum-resistant ovarian cancer.

The company said two of three patients at the current top maintenance dose of SON-1010 had a 'significant tumor response.'

Based on the 'strong safety profile,' a new group using a 25% higher dose will now be studied, the company said.

Topline data from the combination study of the trial are expected in Q4, Sonnet said.

Shares of Sonnet were nearly 3% higher in recent Monday premarket activity.